← Back to Screener
Lunai Bioworks Inc. Common Stock (LNAI)
Price$2.45
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-81.97%
Price vs S&P 500 (4W)-7.19%
VGM Score15.71
Market Capitalization$11.11M
All Metrics
Book Value / Share (Quarterly)$5.44
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.18
Price vs S&P 500 (YTD)-73.41%
EPS (TTM)$-7.63
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-7.63
EPS (Annual)$-10.47
ROI (Annual)-65.78%
Gross Margin (Annual)100.00%
Cash / Share (Quarterly)$0.71
ROA (Last FY)-2162.60%
EBITD / Share (TTM)$-19.45
ROE (5Y Avg)-66.15%
Cash Flow / Share (Annual)$-3.55
P/B Ratio0.13x
P/B Ratio (Quarterly)1.00x
Net Income / Employee (Annual)$-6,137,900
Net Interest Coverage (TTM)-35.32x
ROA (TTM)-1617.78%
EPS Incl Extra (Annual)$-10.47
Current Ratio (Annual)0.04x
Quick Ratio (Quarterly)0.16x
3-Month Avg Trading Volume1.89M
52-Week Price Return-90.22%
Revenue / Employee (TTM)$700
Tangible BV / Share (Quarterly)$5.44
P/S Ratio (Annual)277.70x
Asset Turnover (Annual)0.04x
52-Week High$33.52
EPS Excl Extra (Annual)$-10.47
26-Week Price Return-74.05%
Quick Ratio (Annual)0.02x
13-Week Price Return-15.22%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)0.19x
Enterprise Value$8.94M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5500.00%
Cash / Share (Annual)$0.22
3-Month Return Std Dev374.85%
Net Income / Employee (TTM)$-4,423,600
ROE (Last FY)-67.00%
Net Interest Coverage (Annual)-174.36x
EPS Basic Excl Extra (Annual)$-10.47
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-7.63
ROI (TTM)-64.39%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-114.58%
Year-to-Date Return-65.25%
5-Day Price Return-17.23%
EPS Normalized (Annual)$-10.47
ROA (5Y Avg)-486.61%
Net Profit Margin (Annual)-4350.00%
Month-to-Date Return-20.45%
EBITD / Share (Annual)$-11.11
Operating Margin (Annual)-5300.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-61.91%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-7.63
P/TBV (Quarterly)1.00x
Price vs S&P 500 (13W)-23.48%
Beta0.52x
Revenue / Share (TTM)$0.01
ROE (TTM)-67.00%
52-Week Low$1.21
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LNAILunai Bioworks Inc. Common Stock | — | — | F | $2.45 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Lunai Bioworks is a biopharmaceutical company developing allogeneic cell and gene therapies designed to enhance immune responses and potentially achieve long-term cancer remission. The company's pipeline includes cell therapeutic vaccine candidates RENB-DC11 and RENB-DC20, supported by proprietary AI diagnostics and machine learning platforms that analyze genetic data for earlier cancer detection and clinical insights. Lunai operates through three segments (RENB, BioSymetrics, and RENC) with operations in the United States and Netherlands.